Innovation Hub · Evidence Briefs
White papers for the prescribing clinician.
Open-access evidence syntheses on the therapy areas in which Vyapitus Specialities operates. Written for nephrologists, transplant physicians and other registered healthcare professionals. Updated as the evidence base evolves.
For HCP use only
Library
Currently published
Renal Nutrition · Nuketo® / Nuketo-DS®
Why ketoanalogues matter: rethinking nutrition in pre-dialysis CKD
Pooled Indian CKD prevalence at 13.24 % and rising. KDOQI 2020 vs KDIGO 2024 on low-protein diet. Garneata 2016, Wang 2023, Cochrane 2020 — positive evidence; MDRD long-term and ERIKA 2022 — the honest counter-evidence. Where Nuketo and Nuketo-DS fit, and where they don't.
Transplant · CoverGraf®
Tacrolimus trough-level variability and graft outcomes
Why IPV is now the single most important modifiable predictor of long-term graft outcome. CYP3A5 expresser allele frequency at ~59 % in South Indian recipients and what that means for initial dosing. Once-daily vs twice-daily, DBS and microsampling TDM, CNI minimisation with an antimetabolite.
Transplant · Mycodapt-S™
Mycophenolate sodium in modern kidney transplantation
ERLB301 / ERLB302 equivalence with MMF. The GI tolerability case and the conversion literature (Chan 2006). Where MPA TDM adds value and where it doesn't. EC-MPS in steroid- and CNI-minimisation, plus graded reduction in BK virus and CMV.
Additional briefs on Sevelamer (Sobicoat / Sobicoat-DS), Febuxostat (Nixura) and the gut–kidney axis are in preparation.